Prof Chavez-McGregor speaks to ecancer at BEST OF ASCO® 2018 MIAMI SYMPOSIUM about the PERSEPHONE trial.
PERSEPHONE studies whether women with early breast cancer can safely have trastuzumab for 6 months instead of 12.
Prof Chavez-McGregor describes how the results are generally positive, but also touches upon the drawbacks of the study.